Jiangsu Nhwa Pharmaceutical Co Ltd

Research Jiangsu Nhwa Pharmaceutical Co Ltd (002262.SZ) on Bullrun: market cap CNY 21.70B, P/E 19.7, dividend yield 1.9%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is CNY 21.70B; P/E is 19.7; dividend yield is 1.9%.

Peer valuation comparison

Latest P/E is 19.65x versus a Healthcare sector median of 21.75x (9.6% below).

Latest dividend yield is 1.87% versus a Healthcare sector median of 2.4% (22.1% below).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18CNY 21.70B19.71.9%0.4

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.4 CNY, yield 1.9%.

About Jiangsu Nhwa Pharmaceutical Co Ltd

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Jiangsu Nhwa Pharmaceutical Co Ltd's market cap?

Jiangsu Nhwa Pharmaceutical Co Ltd's market capitalization is CNY 21.70B.

What is Jiangsu Nhwa Pharmaceutical Co Ltd's P/E ratio?

Jiangsu Nhwa Pharmaceutical Co Ltd's price-to-earnings (P/E) ratio is 19.7.

Does Jiangsu Nhwa Pharmaceutical Co Ltd pay a dividend?

Jiangsu Nhwa Pharmaceutical Co Ltd has a dividend yield of 1.9%.

What does Jiangsu Nhwa Pharmaceutical Co Ltd do?

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases.